Glaucoma - Pipeline Review, H2 2018

Date: September 26, 2018
Pages: 308
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G6ABB164C82EN
Leaflet:

Download PDF Leaflet

Glaucoma - Pipeline Review, H2 2018
Glaucoma - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma - Pipeline Review, H2 2018, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glaucoma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 11, 20, 7, 59, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 3 molecules, respectively.

Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Glaucoma - Overview
Glaucoma - Therapeutics Development
Glaucoma - Therapeutics Assessment
Glaucoma - Companies Involved in Therapeutics Development
Glaucoma - Drug Profiles
Glaucoma - Dormant Projects
Glaucoma - Discontinued Products
Glaucoma - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Glaucoma, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Target, H2 2018 (Contd.2), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd.2), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Glaucoma - Pipeline by AC Immune SA, H2 2018
Glaucoma - Pipeline by Aerie Pharmaceuticals Inc, H2 2018
Glaucoma - Pipeline by Allergan Plc, H2 2018
Glaucoma - Pipeline by Altacor Ltd, H2 2018
Glaucoma - Pipeline by Amarantus Bioscience Holdings Inc, H2 2018
Glaucoma - Pipeline by Amgen Inc, H2 2018
Glaucoma - Pipeline by Annexon Inc, H2 2018
Glaucoma - Pipeline by Astellas Pharma Inc, H2 2018
Glaucoma - Pipeline by Bial - Portela & Ca SA, H2 2018
Glaucoma - Pipeline by BioAxone BioSciences Inc, H2 2018
Glaucoma - Pipeline by Can-Fite BioPharma Ltd, H2 2018
Glaucoma - Pipeline by Cellix Bio Pvt Ltd, H2 2018
Glaucoma - Pipeline by Certa Therapeutics Pty Ltd, H2 2018
Glaucoma - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018
Glaucoma - Pipeline by D. Western Therapeutics Institute Inc, H2 2018
Glaucoma - Pipeline by Disarm Therapeutics Inc, H2 2018
Glaucoma - Pipeline by Dompe Farmaceutici SpA, H2 2018
Glaucoma - Pipeline by Elsalys Biotech SA, H2 2018
Glaucoma - Pipeline by EyePoint Pharmaceuticals Inc, H2 2018
Glaucoma - Pipeline by Eyevensys SAS, H2 2018
Glaucoma - Pipeline by Fortress Biotech Inc, H2 2018
Glaucoma - Pipeline by Gene Signal International SA, H2 2018
Glaucoma - Pipeline by Glaukos Corp, H2 2018
Glaucoma - Pipeline by Graybug Vision Inc, H2 2018
Glaucoma - Pipeline by Han Wha Pharma Co Ltd, H2 2018
Glaucoma - Pipeline by Handok Inc, H2 2018
Glaucoma - Pipeline by HitGen LTD, H2 2018
Glaucoma - Pipeline by ID Pharma Co Ltd, H2 2018
Glaucoma - Pipeline by InMed Pharmaceuticals Inc, H2 2018
Glaucoma - Pipeline by Inspyr Therapeutics Inc, H2 2018
Glaucoma - Pipeline by Isarna Therapeutics GmbH, H2 2018
Glaucoma - Pipeline by Kowa Co Ltd, H2 2018
Glaucoma - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2018
Glaucoma - Pipeline by Laboratorios SALVAT SA, H2 2018
Glaucoma - Pipeline by Laboratorios Sophia SA de CV, H2 2018
Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
Glaucoma - Pipeline by MimeTech Srl, H2 2018
Glaucoma - Pipeline by Nemus Bioscience Inc, H2 2018
Glaucoma - Pipeline by Neurim Pharmaceuticals Ltd, H2 2018
Glaucoma - Pipeline by NicOx SA, H2 2018
Glaucoma - Pipeline by NoNO Inc, H2 2018
Glaucoma - Pipeline by Novaliq GmbH, H2 2018
Glaucoma - Pipeline by Novartis AG, H2 2018
Glaucoma - Pipeline by Ocular Therapeutix Inc, H2 2018
Glaucoma - Pipeline by Oculis ehf, H2 2018
Glaucoma - Pipeline by Ohr Pharmaceutical Inc, H2 2018
Glaucoma - Pipeline by Oncolys BioPharma Inc, H2 2018
Glaucoma - Pipeline by Pivot Pharmaceuticals Inc, H2 2018
Glaucoma - Pipeline by Profarma, H2 2018
Glaucoma - Pipeline by Q BioMed Inc, H2 2018
Glaucoma - Pipeline by Quark Pharmaceuticals Inc, H2 2018
Glaucoma - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Glaucoma - Pipeline by ReNetX Bio, H2 2018
Glaucoma - Pipeline by Santen Pharmaceutical Co Ltd, H2 2018
Glaucoma - Pipeline by Senju Pharmaceutical Co Ltd, H2 2018
Glaucoma - Pipeline by Shire Plc, H2 2018
Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018
Glaucoma - Pipeline by Sylentis SAU, H2 2018
Glaucoma - Pipeline by Taejoon Pharm Co Ltd, H2 2018
Glaucoma - Pipeline by TikoMed AB, H2 2018
Glaucoma - Pipeline by Unity Biotechnology Inc, H2 2018
Glaucoma - Dormant Projects, H2 2018
Glaucoma - Dormant Projects, H2 2018 (Contd.1), H2 2018
Glaucoma - Dormant Projects, H2 2018 (Contd.2), H2 2018
Glaucoma - Dormant Projects, H2 2018 (Contd.3), H2 2018
Glaucoma - Dormant Projects, H2 2018 (Contd.4), H2 2018
Glaucoma - Dormant Projects, H2 2018 (Contd.5), H2 2018
Glaucoma - Discontinued Products, H2 2018
Glaucoma - Discontinued Products, H2 2018 (Contd.1), H2 2018

LIST OF FIGURES

Number of Products under Development for Glaucoma, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

COMPANIES MENTIONED

AC Immune SA
Aerie Pharmaceuticals Inc
Allergan Plc
Altacor Ltd
Amarantus Bioscience Holdings Inc
Amgen Inc
Annexon Inc
Astellas Pharma Inc
Bial - Portela & Ca SA
BioAxone BioSciences Inc
Can-Fite BioPharma Ltd
Cellix Bio Pvt Ltd
Certa Therapeutics Pty Ltd
Chong Kun Dang Pharmaceutical Corp
D. Western Therapeutics Institute Inc
Disarm Therapeutics Inc
Dompe Farmaceutici SpA
Elsalys Biotech SA
EyePoint Pharmaceuticals Inc
Eyevensys SAS
Fortress Biotech Inc
Gene Signal International SA
Glaukos Corp
Graybug Vision Inc
Han Wha Pharma Co Ltd
Handok Inc
HitGen LTD
ID Pharma Co Ltd
InMed Pharmaceuticals Inc
Inspyr Therapeutics Inc
Isarna Therapeutics GmbH
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Laboratorios SALVAT SA
Laboratorios Sophia SA de CV
Lee's Pharmaceutical Holdings Ltd
MimeTech Srl
Nemus Bioscience Inc
Neurim Pharmaceuticals Ltd
NicOx SA
NoNO Inc
Novaliq GmbH
Novartis AG
Ocular Therapeutix Inc
Oculis ehf
Ohr Pharmaceutical Inc
Oncolys BioPharma Inc
Pivot Pharmaceuticals Inc
Profarma
Q BioMed Inc
Quark Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
ReNetX Bio
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Shire Plc
Sun Pharma Advanced Research Company Ltd
Sylentis SAU
Taejoon Pharm Co Ltd
TikoMed AB
Unity Biotechnology Inc
Skip to top


Burns - Pipeline Review, H1 2018 US$ 2,000.00 Feb, 2018 · 97 pages

Ask Your Question

Glaucoma - Pipeline Review, H2 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: